Hanger Inc

Hanger — Investor Presentation (November 2013)

24 slides from Hanger's investor presentation, Nov 12, 2013

  1. Slide 1: 150 Years of Empowering Human Potential - Investor Presentation

    150 YEARS Investor Presentation of Empowering Human Potential. November 2013

  2. Slide 2: Safe Harbor

    SAFE HARBOR Except for the historical information contained herein, the matters discussed in this presentation constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. These include, but are not limited to,

  3. Slide 3: Vision

    VISION Be the partner of choice for products and services that enhance human physical capability. 2

  4. Slide 4: Overview

    OVERVIEW LTM net sales of $1.0 billion 2012 adjusted EBITDA* of $166 million 2012 adjusted EPS* of $1.80 Market capitalization of $1.1 billion Two segments: Patient Care – 83% of sales Products & Services – 17% of sales 3 CAGR 9.0% Growth in Adjusted Diluted EPS* Revenue Growth ($ in millions) * Rec

  5. Slide 5: Key Investment Points

    KEY INVESTMENT POINTS Compelling O&P industry growth dynamics Market leader in O&P patient care Proven organic growth and acquisition capabilities Solid financial position Steady margin enhancement Growth opportunities in adjacent markets 4

  6. Slide 6: Patient Care

    PATIENT CARE 5

  7. Slide 7: Patient Care Profile

    PATIENT CARE Over 740 O&P patient-care centers in 45 states Over 1,300 O&P certified and licensed clinicians Treat more than 1,000,000 patients annually Stand alone design, fabricate and fit Delivery through clinics, hospitals and physician offices Network management capability provides value to pay

  8. Slide 8: Market Position - Patient Care

    7 MARKET POSITION PATIENT CARE Only national or regional provider No other provider has more than 2% market share $4.3 Billion Total Addressable Market

  9. Slide 9: Consistent Organic and Acquisition Growth

    PATIENT CARE 8 CONSISTENT ORGANIC AND ACQUISITION GROWTH 5% - 9% Range

  10. Slide 10: Compelling Growth Drivers

    Disease and aging population Advancing technology Regulatory and healthcare reform Increased focus on costs and outcomes COMPELLING GROWTH DRIVERS 10 Sources: Company estimates; Wall Street Research; 2003–2006 National Health and Nutrition Examination Survey; National Institutes of Health; Amputee C

  11. Slide 11: Patient Care Growth Opportunities

    PATIENT CARE First to market with new technologies and products Linkia Network Management Diversification into new adjacent businesses O&P acquisitions Sales synergies across businesses Changing healthcare environment 11 GROWTH OPPORTUNITIES

  12. Slide 12: Products & Services

    PRODUCTS & SERVICES 12

  13. Slide 13: Products & Services Profile

    PRODUCT & SERVICES Distribution: Largest dedicated distributor of O&P devices and components Over 33,000 O&P related items 6 strategically located distribution facilities Manufacture and distribute therapeutic footwear Development and commercialization of new products Rehabilitative Solutions: Value

  14. Slide 14: Products & Services Opportunities

    PRODUCT & SERVICES Increase value proposition of product line Increase penetration of existing customer base Expand market presence geographically Expand into new channels Leverage product development and distribution capabilities Expand O&P fabrication operation to Independent O&P Providers 14 OPPO

  15. Slide 15: Financial Overview

    FINANCIAL OVERVIEW 15

  16. Slide 16: Solid Performance and Stability

    SOLID PERFORMANCE AND STABILITY Earnings and margin growth Substantial cash flow generation Strong balance sheet management Moderate leverage Consistent reduction of leverage 16

  17. Slide 17: Leveraging Revenue Growth

    LEVERAGING REVENUE GROWTH ($ in millions) 14.2% 15.0% 16.4% 17.0% Net Sales Adjusted EBITDA Margin* 17 * Reconciliation to GAAP provided on slides 23 and 24 CAGR 9.0% $753.1 $808.8 $907.8 $947.7 2009 2010 2011 2012

  18. Slide 18: Growth in Adjusted Diluted EPS

    GROWTH IN ADJUSTED DILUTED EPS* 18 Reconciliation to GAAP provided on slides 23 and 24

  19. Slide 19: Steady Comparable Quarter Growth

    STEADY COMPARABLE QUARTER GROWTH 2011 2012 2013 Adjusted EBITDA* ($ in millions) Revenues ($ in millions) Adjusted Earnings Per Diluted Share* 19 * Reconciliation to GAAP provided on slides 23 and 24 $0.15 $0.25 $0.35 $0.45 $0.55 $0.65 Q1 Q2 Q3 Q4 $190 $210 $230 $250 $270 $290 Q1 Q2 Q3 Q4 $15 $25 $3

  20. Slide 20: Solid Cash Flow and Balance Sheet

    SOLID CASH FLOW AND BALANCE SHEET 20 ACP Acquisition 3.6 2.8 3.3 2.8 3.0 Operating Cash Flow Leverage Ratio* ($ in millions) * Reconciliation to GAAP provided on slides 23 and 24 $53 $72 $54 $62 $81 2008 2009 2010 2011 2012

  21. Slide 21: Key Investment Points

    KEY INVESTMENT POINTS Compelling O&P industry growth dynamics Market leader in O&P patient care Proven organic growth and acquisition capabilities Solid financial position Steady margin enhancement Growth opportunities in adjacent markets 21

  22. Slide 22: Appendix

    150 YEARS Appendix of Empowering Human Potential.

  23. Slide 23: Reconciliation of Non-GAAP Financial Measures

    RECONCILIATION OF NON-GAAP FINANCIAL MEASURES 23 Dollars in millions, except per share data 2009 2010 2011 2012 Adjusted EBITDA Reconciliation Income from Operations $ 90.5 $ 80.5 $ 116.0 $ 129.3 Depreciation & Amortization $ 16.3 $ 18.8 $ 31.0 $ 34.7 Relocation expenses - $ 16.4 $ 1.2 - Acquisition

  24. Slide 24: Reconciliation of Non-GAAP Financial Measures

    RECONCILIATION OF NON-GAAP FINANCIAL MEASURES 24 Dollars in millions, except per share data 2011 2012 2013 2013 2013 Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Adjusted EBITDA Reconciliation Income from Operations $ 19.3 $ 32.9 $ 31.2 $ 32.5 $ 116.0 $ 21.7 $ 35.7 $ 35.4 $ 36.5 $ 129.3 $ 22.7 $ 36.6 $ 39

Hanger — Investor Presentation (November 2013) on 6ix